Schering has begun a phase I trial for an optical mammography contrast agent that it developed jointly with Fuji Photo Film. The study will evaluate the agent, called SF64, in conjunction with a CT laser mammography system (CTLM) from Imaging Diagnostic Systems.
The trial will include 40 post-menopausal women at three Berlin institutions: Max Delbrueck Centre for Molecular Medicine, the Charité, and the Helios Klinikum Buch. First results with SF64 in women with suspected breast cancer show good safety and tolerability for the agent, with clear tumor delineation in all patients, according to the Berlin-based firm. Schering expects the study to be completed by mid-2004.
By AuntMinnie.com staff writersSeptember 12, 2003
Related Reading
Currency effects weigh down Schering results, August 8, 2003
Epix, Schering to partner on MRI contrast, May 27, 2003
Schering diagnostics business dips in 2002, February 28, 2003
Peregrine, Schering team up, January 7, 2003
Schering gets Japanese approval for Resovist, October 10, 2002
Copyright © 2003 AuntMinnie.com
